Selective serotonin reuptake inhibitors in affective disorders - II. Efficacy and quality of life

Paul J. Goodnick, Burton J. Goldstein

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Since their introduction, the selective serotonin reuptake inhibitors (SSRIs) have become one of the most widely used classes of medication in psychiatry. Their popularity is based on apparent efficacy over a wide range of disorders and a favorable side-effect profile. However, as with any psychotropic medication, considerable data are required to define where a drug works and where it does not. There is now a wealth of evidence demonstrating that SSRIs may differ in their efficacy profiles in certain depressive symptoms, in different subtypes of depression, with respect to their ability to maintain efficacy over time, on broader outcomes such as quality of life, and in the consistency of the usually effective minimum therapeutic dose across the age spectrum and across indications. Although this review includes data on all SSRIs, it focuses on fluoxetine and sertraline, which in addition to being the most widely used SSRIs are also the most widely studied. The relative quantity and quality of data on these two SSRIs means that it is possible to make relatively firm inferences regarding their differential effects on affective symptoms and quality of life.

Original languageEnglish
JournalJournal of Psychopharmacology
Volume12
Issue number3 SUPPL. B
StatePublished - Dec 18 1998
Externally publishedYes

Fingerprint

Serotonin Uptake Inhibitors
Mood Disorders
Quality of Life
Depression
Sertraline
Affective Symptoms
Aptitude
Fluoxetine
Psychiatry
Pharmaceutical Preparations

Keywords

  • Acute
  • Cognitive dysfunction
  • Continuation
  • Melancholic
  • Psychomotor agitation
  • Quality of life
  • Sleep disturbance

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Pharmacology (medical)

Cite this

Selective serotonin reuptake inhibitors in affective disorders - II. Efficacy and quality of life. / Goodnick, Paul J.; Goldstein, Burton J.

In: Journal of Psychopharmacology, Vol. 12, No. 3 SUPPL. B, 18.12.1998.

Research output: Contribution to journalArticle

@article{ef89c8d2e6d74cccb41bf01cd54d7bfa,
title = "Selective serotonin reuptake inhibitors in affective disorders - II. Efficacy and quality of life",
abstract = "Since their introduction, the selective serotonin reuptake inhibitors (SSRIs) have become one of the most widely used classes of medication in psychiatry. Their popularity is based on apparent efficacy over a wide range of disorders and a favorable side-effect profile. However, as with any psychotropic medication, considerable data are required to define where a drug works and where it does not. There is now a wealth of evidence demonstrating that SSRIs may differ in their efficacy profiles in certain depressive symptoms, in different subtypes of depression, with respect to their ability to maintain efficacy over time, on broader outcomes such as quality of life, and in the consistency of the usually effective minimum therapeutic dose across the age spectrum and across indications. Although this review includes data on all SSRIs, it focuses on fluoxetine and sertraline, which in addition to being the most widely used SSRIs are also the most widely studied. The relative quantity and quality of data on these two SSRIs means that it is possible to make relatively firm inferences regarding their differential effects on affective symptoms and quality of life.",
keywords = "Acute, Cognitive dysfunction, Continuation, Melancholic, Psychomotor agitation, Quality of life, Sleep disturbance",
author = "Goodnick, {Paul J.} and Goldstein, {Burton J.}",
year = "1998",
month = "12",
day = "18",
language = "English",
volume = "12",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "3 SUPPL. B",

}

TY - JOUR

T1 - Selective serotonin reuptake inhibitors in affective disorders - II. Efficacy and quality of life

AU - Goodnick, Paul J.

AU - Goldstein, Burton J.

PY - 1998/12/18

Y1 - 1998/12/18

N2 - Since their introduction, the selective serotonin reuptake inhibitors (SSRIs) have become one of the most widely used classes of medication in psychiatry. Their popularity is based on apparent efficacy over a wide range of disorders and a favorable side-effect profile. However, as with any psychotropic medication, considerable data are required to define where a drug works and where it does not. There is now a wealth of evidence demonstrating that SSRIs may differ in their efficacy profiles in certain depressive symptoms, in different subtypes of depression, with respect to their ability to maintain efficacy over time, on broader outcomes such as quality of life, and in the consistency of the usually effective minimum therapeutic dose across the age spectrum and across indications. Although this review includes data on all SSRIs, it focuses on fluoxetine and sertraline, which in addition to being the most widely used SSRIs are also the most widely studied. The relative quantity and quality of data on these two SSRIs means that it is possible to make relatively firm inferences regarding their differential effects on affective symptoms and quality of life.

AB - Since their introduction, the selective serotonin reuptake inhibitors (SSRIs) have become one of the most widely used classes of medication in psychiatry. Their popularity is based on apparent efficacy over a wide range of disorders and a favorable side-effect profile. However, as with any psychotropic medication, considerable data are required to define where a drug works and where it does not. There is now a wealth of evidence demonstrating that SSRIs may differ in their efficacy profiles in certain depressive symptoms, in different subtypes of depression, with respect to their ability to maintain efficacy over time, on broader outcomes such as quality of life, and in the consistency of the usually effective minimum therapeutic dose across the age spectrum and across indications. Although this review includes data on all SSRIs, it focuses on fluoxetine and sertraline, which in addition to being the most widely used SSRIs are also the most widely studied. The relative quantity and quality of data on these two SSRIs means that it is possible to make relatively firm inferences regarding their differential effects on affective symptoms and quality of life.

KW - Acute

KW - Cognitive dysfunction

KW - Continuation

KW - Melancholic

KW - Psychomotor agitation

KW - Quality of life

KW - Sleep disturbance

UR - http://www.scopus.com/inward/record.url?scp=0031792537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031792537&partnerID=8YFLogxK

M3 - Article

C2 - 9808078

AN - SCOPUS:0031792537

VL - 12

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 3 SUPPL. B

ER -